Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Neuronetics, Inc. logo — Non-drug, safe, effective treatment for depression and other...

Neuronetics, Inc.

Non-drug, safe, effective treatment for depression and other mental health conditions.

Founded 2003 United States Malvern, United States 220 employees Post Ipo Debt Total: $373.40M Biotechnology, Health Care +3

General Information

Company Name Neuronetics, Inc.
Founded Year 2003
Location United States Malvern, United States +1
Founders / Decision Makers
Judy P. Ways — Vice President, Regulatory Affairs and Quality Assurance
Employees 220
Industries Biotechnology, Health Care, Health and Wellness +2
Funding Stage Post Ipo Debt
Social

Get notified when Neuronetics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Neuronetics, Inc.

Neuronetics, Inc. is a U.S.-based public medical device company specializing in non-drug, safe, and effective treatments for depression and other mental health conditions. Established in 2003, Neuronetics is the innovator behind NeuroStar Advanced Therapy, the leading Transcranial Magnetic Stimulation (TMS) solution for Major Depressive Disorder and other mental health issues. The company's strategic vision revolves around revolutionizing patient care with top-tier neurohealth therapies. NeuroStar has set itself apart as the leading TMS choice among physicians, with over 6.4 million treatments administered. Notably, it is a non-invasive, outpatient treatment that takes as little as 20 minutes per session for 36 sessions, promoting neuroplasticity to target mental health at its core—the brain. Neuronetics markets NeuroStar Advanced Therapy in the U.S. and several global markets, positioning itself as a key player in the Biotechnology, Health Care, and Manufacturing industries. In a recent funding development, Neuronetics secured a notable $60.00M Post-IPO Debt investment on April 4, 2023, with SLR Capital Partners participating as the investor. This investment underlines the confidence in Neuronetics' approach and potentially signifies a significant growth phase for the company.

Taxonomy: TMS Therapy, Neuropsychiatric Treatment, Non-invasive Therapy, Mental Health, Medical Device, Neurological Disorders, Transcranial Magnetic Stimulation, Neuroplasticity, Depression Treatment, Outpatient Treatment, Medical Technology, MRI-Strength Magnetic Field Pulses, Psychiatric Disorders, Neurohealth Therapies, Neuronetics

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $60.00M 1 SLR Capital Partners 04 Apr 2023
Post-IPO Equity Unknown 1 J Carlo Cannell 27 Jun 2022
Post-IPO Equity $80.60M - 02 Feb 2021
Post-IPO Debt $15.00M 1 Solar capital 20 Dec 2020
Debt Financing $50.00M - 01 Jan 2020

View All 12 Funding Rounds

Neuronetics, Inc. Alternatives & Competitors

Neuronetics, Inc. vs
Kadima Neuropsychiatry Institute
Kadima Neuropsychiatry Institute United States

Our mission is to utilize innovation and compassion to help our patients advance forward to a more f...

24 employees
Health Care, Health and Wellness
Compare Neuronetics, Inc. vs Kadima Neuropsychiatry Institute
Neuronetics, Inc. vs
TMS Clinics Of Canada
TMS Clinics Of Canada Canada

Using breakthrough technology, professionalism, and compassion to better lives. TMS Of Canada, Love...

3 employees
Health Care, Health and Wellness
Neuronetics, Inc. vs
Serenity Healthcare
Serenity Healthcare United States

Take back your life.

450 employees
Health Care, Life insurance
Compare Neuronetics, Inc. vs Serenity Healthcare
Also compare with: Neuronetics, Inc. vs Greenbrook Greenbrook

FAQ About Neuronetics, Inc.

Non-drug, safe, effective treatment for depression and other mental health conditions.
Neuronetics, Inc. was founded in 2003.
Neuronetics, Inc. is headquartered in Malvern, United States.
Neuronetics, Inc. operates in the following industries: Biotechnology, Health Care, Health and Wellness, Manufacturing, Medical Devices.
Neuronetics, Inc. has approximately 220 employees.
Neuronetics, Inc. has completed 12 funding rounds, raising a total of $373.40M. The latest funding stage is Post Ipo Debt.
Top alternatives and competitors to Neuronetics, Inc. include Kadima Neuropsychiatry Institute, TMS Clinics Of Canada, Serenity Healthcare, Greenbrook, Stella Mental Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neuronetics, Inc. and Kadima Neuropsychiatry Institute are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Neuronetics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy